Harbour BioMed, a Shanghai-based biotechnology company focusing on cancer screening, today announced completion of its US$102.8 Million series C round financing to accelerate development of its growing portfolio of next generation biologics targeting cancer, immunologic diseases, and COVID-19. The financing was led by Hudson Bay Capital; followed by OrbiMed, Country Garden VC, GTJA Investment Group, […] Chinese Biotech Startup Harbour BioMed Secures $102.8M In Series C Round comes from China Money Network: Primary Data for China's Primary Markets! All Rights Reserved.